Can-Fite BioPharma Pancreatic Cancer Study Hits Enrollment Milestone
Ticker: CANF · Form: 6-K · Filed: Jul 30, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Jul 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, drug-development, milestone
TL;DR
Can-Fite BioPharma's pancreatic cancer drug Namodenoson study is over 50% enrolled. Bullish.
AI Summary
On July 30, 2025, Can-Fite BioPharma Ltd. announced that its Phase 2a study for pancreatic cancer, utilizing its drug Namodenoson, has achieved over a 50% enrollment milestone. This update was provided in a press release furnished as part of their 6-K filing.
Why It Matters
Achieving enrollment milestones is crucial for advancing drug development, indicating progress towards potential new treatments for pancreatic cancer.
Risk Assessment
Risk Level: medium — Clinical trial progress is a key indicator, but success is not guaranteed, and regulatory approval is still a long way off.
Key Numbers
- 50% — Enrollment Milestone (Indicates significant progress in the Phase 2a study for pancreatic cancer.)
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Issuer of the filing and developer of Namodenoson.
- Namodenoson (drug) — The drug being studied for pancreatic cancer.
- July 30, 2025 (date) — Date of the press release announcing the enrollment milestone.
FAQ
What is the specific drug Can-Fite BioPharma is testing for pancreatic cancer?
The drug being tested is Namodenoson.
What stage is the pancreatic cancer study for Namodenoson currently in?
The study is a Phase 2a study.
What significant event was announced regarding the pancreatic cancer study?
The study achieved over a 50% enrollment milestone.
On what date was this enrollment milestone announced?
The announcement was made on July 30, 2025.
What type of SEC filing is this report?
This is a Form 6-K report, which is a Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 30, 2025 regarding Can-Fite BioPharma Ltd. (CANF).